Compare LMNR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMNR | ALXO |
|---|---|---|
| Founded | 1893 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 240.8M |
| IPO Year | 2005 | 2020 |
| Metric | LMNR | ALXO |
|---|---|---|
| Price | $12.69 | $1.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $20.00 | $3.50 |
| AVG Volume (30 Days) | 53.7K | ★ 691.4K |
| Earning Date | 06-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,723,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.20 | $0.41 |
| 52 Week High | $17.11 | $2.66 |
| Indicator | LMNR | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 50.74 |
| Support Level | $12.54 | $1.44 |
| Resistance Level | $14.86 | $2.27 |
| Average True Range (ATR) | 0.36 | 0.14 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 2.53 | 41.18 |
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.